Internal and Emergency Medicine

, Volume 8, Issue 1, pp 23–32

Disseminated intravascular coagulation: a review for the internist



Disseminated intravascular coagulation (DIC) is a syndrome characterized by systemic intravascular activation of coagulation, leading to widespread deposition of fibrin in the circulation. Recent knowledge on important pathogenetic mechanisms that may lead to DIC has resulted in novel preventive and therapeutic approaches to patients with DIC. The diagnosis of DIC can be made by sensitive laboratory tests; however, most of these tests are not readily available in a clinical setting. A reliable diagnosis can also be made on the basis of a small series of laboratory tests that can be combined in a scoring algorithm. The cornerstone of the management of DIC is the specific and vigorous treatment of the underlying disorder. Strategies aimed at the inhibition of coagulation activation may theoretically be justified and have been found beneficial in experimental and clinical studies. These strategies comprise inhibition of tissue factor-mediated activation of coagulation or restoration of physiological anticoagulant pathways.


Disseminated intravascular coagulation Thrombin Tissue factor Inflammation Coagulation Anticoagulants Fibrinolysis 


  1. 1.
    Levi M, Seligsohn U (2010) Disseminated intravascular coagulation. In: Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U (eds) Williams hematology. McGraw Hill, PhiladelphiaGoogle Scholar
  2. 2.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341:586–592PubMedCrossRefGoogle Scholar
  3. 3.
    Levi M (2007) Disseminated intravascular coagulation. Crit Care Med 35:2191–2195PubMedCrossRefGoogle Scholar
  4. 4.
    Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38:S26–S34PubMedCrossRefGoogle Scholar
  5. 5.
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedCrossRefGoogle Scholar
  6. 6.
    Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2:1924–1933PubMedCrossRefGoogle Scholar
  7. 7.
    Levi M, Opal SM (2006) Coagulation abnormalities in critically ill patients. Crit Care 10:222PubMedCrossRefGoogle Scholar
  8. 8.
    Anas AA, Wiersinga WJ, de Vos AF, van der Poll T (2010) Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 68:147–152PubMedGoogle Scholar
  9. 9.
    Levi M, de Jonge E, van der Poll T (2001) Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 29(7 Suppl):S90–S94PubMedCrossRefGoogle Scholar
  10. 10.
    Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86(1):51–56PubMedGoogle Scholar
  11. 11.
    Levi M (2002) The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med 30:1914–1915PubMedCrossRefGoogle Scholar
  12. 12.
    Lowenberg EC, Meijers JC, Levi M (2010) Platelet–vessel wall interaction in health and disease. Neth J Med 68:242–251PubMedGoogle Scholar
  13. 13.
    Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9(Suppl 1):S9–S14PubMedGoogle Scholar
  14. 14.
    Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10:171–178PubMedCrossRefGoogle Scholar
  15. 15.
    de Jonge E, Friederich PW, Levi M, van der Poll T (2003) Activation of coagulation by administration of recombinant factor VIIa elicits interleukin-6 and interleukin-8 release in healthy human subjects. Clin Diagn Lab Immunol 10:495–497PubMedGoogle Scholar
  16. 16.
    Levi M (2010) Disseminated intravascular coagulation: a disease-specific approach. Semin Thromb Hemost 36:363–365PubMedCrossRefGoogle Scholar
  17. 17.
    Seligsohn U (2000) Disseminated intravascular coagulation. In: Handin RI, Lux SE, Stossel TP (eds) Blood: principles and practice of hematology. J.B.Lippingcott, PhiladelphiaGoogle Scholar
  18. 18.
    Keller TT, Mairuhu AT, de Kruif MD, Klein SK, Gerdes VE, ten Cate H, Brandjes DP, Levi M, Van Gorp EC (2003) Infections and endothelial cells. Cardiovasc Res 60:40–48PubMedCrossRefGoogle Scholar
  19. 19.
    Gando S, Nakanishi Y, Tedo I (1995) Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 23:1835–1842PubMedCrossRefGoogle Scholar
  20. 20.
    Levi M (2009) Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period. Thromb Res 123:S63–S64PubMedCrossRefGoogle Scholar
  21. 21.
    Colman RW, Rubin RN (1990) Disseminated intravascular coagulation due to malignancy. Semin Oncol 17:172–186PubMedGoogle Scholar
  22. 22.
    Barbui T, Falanga A (2001) Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 27:593–604PubMedCrossRefGoogle Scholar
  23. 23.
    Fisher DF Jr, Yawn DH, Crawford ES (1983) Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg 118:1252–1255PubMedCrossRefGoogle Scholar
  24. 24.
    Isbister GK (2010) Snake bite doesn’t cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost 36:444–451PubMedCrossRefGoogle Scholar
  25. 25.
    Levi M, Meijers JC (2011) DIC: which laboratory tests are most useful? Blood Rev 25:33–37PubMedCrossRefGoogle Scholar
  26. 26.
    Dempfle CE, Borggrefe M (2008) Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 34:445–450PubMedCrossRefGoogle Scholar
  27. 27.
    Toh CH, Samis J, Downey C, Walker J, Becker L, Brufatto N, Tejidor L, Jones G, Houdijk W, Giles A, Koschinsky M, Ticknor LO, Paton R, Wenstone R, Nesheim M (2002) Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 100:2522–2529PubMedCrossRefGoogle Scholar
  28. 28.
    Toh CH (2002) Transmittance waveform of routine coagulation tests is a sensitive and specific method for diagnosing non-overt disseminated intravascular coagulation. Blood Rev 16(Suppl 1):S11–S14PubMedGoogle Scholar
  29. 29.
    Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330PubMedGoogle Scholar
  30. 30.
    Toh CH, Hoots WK (2007) The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a five year overview. J Thromb Haemost 5:604–606PubMedCrossRefGoogle Scholar
  31. 31.
    Wada H, Hatada T, Okamoto K, Uchiyama T, Kawasugi K, Mayumi T, Gando S, Kushimoto S, Seki Y, Madoiwa S, Okamura T, Toh CH (2010) Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 85:691–694PubMedCrossRefGoogle Scholar
  32. 32.
    Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H (1995) Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 74:848–852PubMedGoogle Scholar
  33. 33.
    Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S (2006) A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 34:625–631PubMedGoogle Scholar
  34. 34.
    Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami K (2009) Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma. Thromb Res 124:706–710PubMedCrossRefGoogle Scholar
  35. 35.
    Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33:341–348PubMedCrossRefGoogle Scholar
  36. 36.
    Kinasewitz GT, Zein JG, Lee GL, Nazir SR, Taylor FB Jr (2005) Prognostic value of a simple evolving DIC score in patients with severe sepsis. Crit Care Med 33:221–225CrossRefGoogle Scholar
  37. 37.
    Tromp M, Tjan DH, van Zanten AR, Gielen-Wijffels SE, Goekoop GJ, van den Boogaard M, Wallenborg CM, Biemond-Moeniralam HS, Pickkers P (2011) The effects of implementation of the Surviving Sepsis Campaign in the Netherlands. Neth J Med 69:292–298PubMedGoogle Scholar
  38. 38.
    Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145:24–33PubMedCrossRefGoogle Scholar
  39. 39.
    Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL (2007) Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 176:483–490PubMedCrossRefGoogle Scholar
  40. 40.
    Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMedCrossRefGoogle Scholar
  41. 41.
    Afshari A, Wetterslev J, Brok J, Møller AM (2008) Antithrombin III for critically ill patients. Cochrane Database Syst Rev CD005370Google Scholar
  42. 42.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709PubMedCrossRefGoogle Scholar
  43. 43.
    Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, GÑrdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD (2012) Drotrecogin Alfa (Activated) in adults with septic shock. N Engl J Med 366:2055–2064PubMedCrossRefGoogle Scholar
  44. 44.
    Thachil J, Toh CH, Levi M, Watson HG (2012) The withdrawal of activated protein C from the use in patients with severe sepsis and DIC. Br J Haematol 157:493–494PubMedCrossRefGoogle Scholar
  45. 45.
    Arul GS, Sacks L, Wolf A, Gargan M, Spicer RD (1998) Protein-C concentrate for meningococcal purpura fulminans. Lancet 351:988–989PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2012

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Amsterdam, Academic Medical CenterAmsterdamThe Netherlands
  2. 2.Center of Experimental Molecular MedicineUniversity of Amsterdam, Academic Medical CenterAmsterdamThe Netherlands
  3. 3.Center of Infection and Immunity AmsterdamUniversity of Amsterdam, Academic Medical CenterAmsterdamThe Netherlands

Personalised recommendations